Antares Prof High Growth Shares (PPL0106AU) Report & Performance

What is the Antares Prof High Growth Shares fund?

Antares Prof High Growth Shares aims to outperform the S&P/ASX 200 Accumulation Index (‘Benchmark’) by 5% per annum (before fees) over a rolling five year period. The Fund seeks to enhance returns through a range of investment strategies including long/short positions and active trading. The fund is an actively managed portfolio of Australian listed equities and cash equivalent instruments, with exchange traded derivatives used for efficient portfolio management, to hedge market risks and to enhance returns.

Growth of $1000 Investment Over Time

Performance Report

Peer Comparison Report

Peer Comparison Report

Latest News & Updates For Antares Prof High Growth Shares

Antares Prof High Growth Shares Fund Commentary September 30, 2023

The Australian market was not exempt from the decline in global shares. The Real Estate and Information Technology sectors led the market declines given concerns about the impact of higher interest rates for longer. Healthcare and Consumer Discretionary sectors were sold down on worry about the consumer’s ability to tolerate higher inflation and interest rates. The Resources sector proved more resilient given the surprising rise in iron ore prices to US$120 per ton despite a weak Chinese property sector. The only positive sector was Energy on the back of higher oil prices.

The Antares High Growth Shares Fund delivered a return of -3.5% (net of fees) for the month of September 2023, compared to its benchmark’s -2.8% return.

Contributing to performance were overweight positions in Paladin (PDN) and Santos (STO) together with a short position in Orora (ORA). The uranium price rose to a decade high in September and with further increases expected as investors anticipated greater future demand for nuclear energy. PDN’s share price rose by more than 25% in September. The higher oil price helped boost the Santos share price. Early in September, ORA announced the acquisition of global high end wine and spirits glass bottles producer Saverglass for A$2.1bn. Simultaneously it announced it would partially fund this via proposed A$1.3bn institutional and retail equity raisings.

Detracting value were overweight positions in Botanix (BOT), Block Inc (SQ2) and Goodman Group (GMG). During the month BOT announced that the FDA had delayed approval of its Sofpironium Bromide product because the instructions for patients need amendment. While the FDA did not raise any safety, efficacy or manufacturing issues, BOT expects approval is now likely to be delayed until the second half of CY24. SQ2 suffered a small outage in its Square Seller retail point of sale equipment globally which hurt sentiment, while the march up in longer duration interest rates hurt its valuation as discount rates spiked, disproportionately impacting longer duration equities such as SQ2. GMG shares were weaker in September on no particular news. Property related stocks were sold down as bond yields moved higher.

Australia’s economy continues to display significant signs of slowing down with inflation concerns. Retail spending is subdued as consumers struggle with the squeeze from higher prices, rising mortgage interest rates and rents. Consumer annual inflation rose from 4.9% in July to 5.2% in August largely on the back of higher fuel prices according to the ABS monthly indicator. Employment has been a positive surprise with strong job gains in August despite lower vacancies. The Reserve Bank again held the cash interest rate steady at 4.1% but maintained guidance that further interest rate rises may be required to get inflation back to their target range of 2% to 3%.

READ HISTORICAL PERFORMANCE COMMENTARIES

Product Snapshot

  • Performance Review
  • Product Overview
  • Peer Comparison
  • Product Details

Performance Review

Fund Name Last Month
? Returns after fees in the most recent (last) month).
3 Months Return
? Returns after fees in the most recent 3 months.
1 Year Return
? Trailing 12 month returns.
3 Years Average Return
? Average Annual returns from the last 3 years.
Since Inc. Average Return
? Average (annualised) returns since inception
1 Year Std. Dev. (Annual)
? The standard deviation (or annual volatility) of the last 12 months.
3 Years Std. Dev. (Annual)
? The average standard deviation (or annual volatility) from the last 3 years.
Since Inc. Std. Dev. (Annual)
? The average standard deviation (or annual volatility) since the fund inception.
1 Year Max Drawdown
? The maximum drawdown in the last 12 months - a drawdown is a peak-to-trough decline during a specific period for an investment, trading account, or fund.
3 Year Max Drawdown
? The maximum drawdown in the last 36 months - a drawdown is a peak-to-trough decline during a specific period for an investment, trading account, or fund.
Since Inc. Max Drawdown
? The maximum drawdown since inception - a drawdown is a peak-to-trough decline during a specific period for an investment, trading account, or fund.
Antares Prof High Growth Shares3.52%6.76%20.34%7.26%10.75%9.24%13.53%13.98%-2.9%-13.72%-39.1%

Product Overview

Peer Comparison

Product Details

Product Due Diligence

What is Antares Prof High Growth Shares

Antares Prof High Growth Shares is an Managed Funds investment product that is benchmarked against ASX Index 200 Index and sits inside the Domestic Equity - Long Short Index. Think of a benchmark as a standard where investment performance can be measured. Typically, market indices like the ASX200 and market-segment stock indexes are used for this purpose. The Antares Prof High Growth Shares has Assets Under Management of 401.02 M with a management fee of 1.05%, a performance fee of 0.00% and a buy/sell spread fee of 0.3%.

How has the investment product performed recently?

How is risk measured in this investment product?

What is the relative performance of the investment product?

Does the investment product produce Alpha over its Peers?

What are similar investment products?

What level of diversification will Antares Prof High Growth Shares provide?

How do I compare the investment product with its peers?

How do I compare the Antares Prof High Growth Shares with the ASX Index 200 Index?

Can I sort and compare the Antares Prof High Growth Shares to do my own analysis?

Has the Antares Prof High Growth Shares been independently verified by SMSF Mate?

How can I invest in Antares Prof High Growth Shares?

How do I get in contact with the Antares Prof High Growth Shares?

Comments from SMSF Mates

Video Gallery

No current media available.

Historical Performance Commentary

Performance Commentary - August 31, 2023

Australian shares disappointed in August with a mild decline given concerns over China’s prospects as well as the Australian consumer. The Utilities and Consumer Staples sectors led the market declines given concerns about the consumer’s ability to absorb higher electricity & gas prices as well as rising mortgage interest rates and rents. Information Technology declined in line with a more cautious view after their recent strong gains. Despite a rebound in the iron ore price to above US$110 per ton, the Resources sector posted a -1.8% negative return with concerns over China’s prospects. There were some positives with surprisingly strong gains for Consumer Discretionary and Real Estate on hopes that the Reserve Bank has ceased raising interest rates.

August is also reporting season for most Australian companies and while results were largely in line with expectations, the prospect of rising costs and a slowing economy saw reasonably soft guidance for the FY24 year which flowed through to earnings downgrades. Sector allocation The Antares High Growth Shares Fund returned -3.0% (net of fees) for the month of August 2023, compared to its benchmark’s -0.7% return.

Detracting value were overweight positions in Iress (IRE), Resmed Inc (RES) and Block Inc (SQ2). IRE’s result was accompanied by its fourth material earnings downgrade in 12 months, citing cost pressures and a weaker revenue outlook.

The company also announced that it would suspend its interim dividend. RES’ 4Q result was below market expectations, driven by lower margins and higher costs. There is also some concern that the increased use of Ozempic for weight loss could reduce the prospect of sleep apnoea and subsequent demand for RES’ machines. Compounding this was the release of clinical trial results by Novo Nordisk, the manufacturer of Ozempic that indicated another of its weight loss products, Wegovy, could reduce the risk of serious heart problems and heart-related death by 20%. Having risen by more than 21% in July, SQ2 shares were sold down in August after reporting its 2Q23 results. This was despite the company exceeding expectations and upgrading full year EBITDA guidance. The decline appears to be driven by the outlook provided by management whereby 3Q23 gross margins were decelerating, as well as overall macroeconomic concerns. A material portion of SQ2’s earnings are exposed to transaction volumes Top 10 share holdings (alphabetical order) in small and medium sized businesses, which are adversely impacted by a slowdown in US consumer spending.

Performance Commentary - July 31, 2023

Performance Commentary - June 30, 2023

Performance Commentary - May 31, 2023

Performance Commentary - April 30, 2023

Performance Commentary - March 31, 2023

Performance Commentary - February 28, 2023

Kind words from Aussies managing
their own self funded futures

  • SMSF Mate is a unique website because it has ideas about how to approach SMSFs, insurance and other financial topics that come straight from first hand experience. It's much more useful than what you find on all the other financial websites that just offer generic info that you could easily get on the ATO's website. It's also nice to know there's no financial incentive behind the information, it's legitimately there to help people understand self-managed super funds and how to get the most out of them, not to get an affiliate commission from a broker or other financial services provider. The investment product information is also incredibly useful, I've never seen this kind of functionality on any other website that let's you look at such a wide range of products, sort by what info is most interesting or important to you, and subscribe to updates for different funds and financial products all in one place. Definitely worth checking out if you own or are considering an SMSF!

    David G, Self-Employed, SMSF Owner